Genetic and non-genetic animal models for autism spectrum disorders (ASD)

Reproductive Toxicology

Volumn 64, Issue , 2016, Pages 116-140

  Ergaz, Zivanit ^a   Weinstein Fudim, Liza ^a   Ornoy, Asher ^a  

^a HEBREW UNIVERSITY   (Israel)

Author keywords

ASD; Environmental; Genetic; Inflammation; Mice; Rats; VPA

Indexed keywords

ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; APC PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN PROTEIN; CALCIUM CHANNEL L TYPE; CONTACTIN; CONTACTIN ASSOCIATED PROTEIN LIKE 2; FRAGILE X MENTAL RETARDATION PROTEIN; GLUCOSE TRANSPORTER; ISLET BRAIN 2 PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; METABOTROPIC RECEPTOR; METHYL CPG BINDING PROTEIN 2; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUREXIN; NEUREXIN 1 ALPHA; NEUROLIGIN; PARVALBUMIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PSYCHOTROPIC AGENT; RISPERIDONE; SEROTONIN; SEROTONIN 2C RECEPTOR; SEROTONIN TRANSPORTER; TIANEPTINE; TUBERIN; UBIQUITIN PROTEIN LIGASE E3; UBIQUITIN PROTEIN LIGASE E3 ALPHA; UNCLASSIFIED DRUG; VALPROIC ACID;

ALLELE; ANIMAL MODEL; ARTICLE; AUTISM; BEHAVIOR THERAPY; BRAIN SIZE; CORTICAL DYSPLASIA; DOWN REGULATION; EXPERIMENTAL BEHAVIORAL TEST; FOCAL EPILEPSY; FRAGILE X SYNDROME; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GENETIC DISORDER; GENETIC MANIPULATION; GENETIC MODEL; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HETEROZYGOSITY; HUMAN; MOUSE MODEL; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN; PHELAN-MCDERMID SYNDROME; PRADER WILLI SYNDROME; PRENATAL EXPOSURE; RAT MODEL; RETT SYNDROME; SEX DIFFERENCE; SIGNAL TRANSDUCTION; SYNAPSE; TIMOTHY SYNDROME; TUBEROUS SCLEROSIS; ANIMAL; ANIMAL BEHAVIOR; CHEMICALLY INDUCED; DISEASE MODEL; FEMALE; GENETIC EPIGENESIS; GENETICS; MUTATION; PREGNANCY; PSYCHOLOGY;

ANIMALS; AUTISM SPECTRUM DISORDER; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; EPIGENESIS, GENETIC; FEMALE; MUTATION; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; VALPROIC ACID;

EID: 84971278975     PISSN: 08906238     EISSN: 18731708     Source Type: Journal    
DOI: 10.1016/j.reprotox.2016.04.024     Document Type: Article

References (156)

1. [1] Diagnostic and Statistical Manual of Mental Disorders, 5th ed., Washington DC, 2013.
2. [2] Kogan, M.D., Blumberg, S.J., Schieve, L.A., Boyle, C.A., Perrin, J.M., Ghandour, R.M., et al. Prevalence of parent-reported diagnosis of autism spectrum disorder among children in the US, 2007. Pediatrics 124 (2009), 1395–1403.
3. [3] Tchaconas, A., Adesman, A., Autism spectrum disorders: a pediatric overview and update. Curr. Opin. Pediatr. 25 (2013), 130–144.
4. [4] Ornoy, A., Weinstein-Fudim, L., Ergaz, Z., Prenatal factors associated with autism spectrum disorder (ASD). Reprod. Toxicol. 56 (2015), 155–169.
5. [5] Chen, J.A., Penagarikano, O., Belgard, T.G., Swarup, V., Geschwind, D.H., The emerging picture of autism spectrum disorder: genetics and pathology. Annu. Rev. Pathol. 10 (2015), 111–144.
6. [6] Christianson, A.L., Chesler, N., Kromberg, J.G., Fetal valproate syndrome: clinical and neuro-developmental features in two sibling pairs. Dev. Med. Child Neurol. 36 (1994), 361–369.
7. [7] Moore, S.J., Turnpenny, P., Quinn, A., Glover, S., Lloyd, D.J., Montgomery, T., et al. A clinical study of 57 children with fetal anticonvulsant syndromes. J. Med. Genet. 37 (2000), 489–497.
8. [8] Rodier, P.M., Ingram, J.L., Tisdale, B., Croog, V.J., Linking etiologies in humans and animal models: studies of autism. Reprod. Toxicol. 11 (1997), 417–422.
9. [9] Chadman, K.K., Yang, M., Crawley, J.N., Criteria for validating mouse models of psychiatric diseases. Am. J. Med. Genet. B Neuropsychiatr. Genet. 150B (2009), 1–11.
10. [10] Kaiser-McCaw, B., Hecht, F., Cadien, J.D., Moore, B.C., Fragile X-linked mental retardation. Am. J. Med. Genet. 7 (1980), 503–505.
11. [11] Meloni, I., Bruttini, M., Longo, I., Mari, F., Rizzolio, F., D'Adamo, P., et al. A mutation in the rett syndrome gene, MECP2, causes X-linked mental retardation and progressive spasticity in males. Am. J. Hum. Genet. 67 (2000), 982–985.
12. [12] Green, A.J., Johnson, P.H., Yates, J.R., The tuberous sclerosis gene on chromosome 9q34 acts as a growth suppressor. Hum. Mol. Genet. 3 (1994), 1833–1834.
13. [13] Gillis, J., Burashnikov, E., Antzelevitch, C., Blaser, S., Gross, G., Turner, L., et al. Long QT, syndactyly, joint contractures, stroke and novel CACNA1C mutation: expanding the spectrum of Timothy syndrome. Am. J. Med. Genet. A 158A (2012), 182–187.
14. [14] Ogata, H., Ihara, H., Murakami, N., Gito, M., Kido, Y., Nagai, T., Autism spectrum disorders and hyperactive/impulsive behaviors in Japanese patients with Prader-Willi syndrome: a comparison between maternal uniparental disomy and deletion cases. Am. J. Med. Genet. A 164A (2014), 2180–2186.
15. [15] Yasuda, Y., Hashimoto, R., Fukai, R., Okamoto, N., Hiraki, Y., Yamamori, H., et al. Duplication of the NPHP1 gene in patients with autism spectrum disorder and normal intellectual ability: a case series. Ann. Gen. Psychiatry, 13, 2014, 22.
16. [16] Hamilton, S.M., Green, J.R., Veeraragavan, S., Yuva, L., McCoy, A., Wu, Y., et al. Fmr1 and Nlgn3 knockout rats: novel tools for investigating autism spectrum disorders. Behav. Neurosci. 128 (2014), 103–109.
17. [17] Stewart, A.M., Nguyen, M., Wong, K., Poudel, M.K., Kalueff, A.V., Developing zebrafish models of autism spectrum disorder (ASD). Prog. Neuropsychopharmacol. Biol. Psychiatry. 50 (2014), 27–36.
18. [18] Panaitof, S.C., A songbird animal model for dissecting the genetic bases of autism spectrum disorder. Dis. Markers 33 (2012), 241–249.
19. [19] Cyranoski, D., Monkeys genetically modified to show autism symptoms. Nature, 529, 2016, 449.
20. [20] Oddi, D., Subashi, E., Middei, S., Bellocchio, L., Lemaire-Mayo, V., Guzman, M., et al. Early social enrichment rescues adult behavioral and brain abnormalities in a mouse model of fragile X syndrome. Neuropsychopharmacology 40 (2015), 1113–1122.
21. [21] Bhattacharya, A., Kaphzan, H., Alvarez-Dieppa, A.C., Murphy, J.P., Pierre, P., Klann, E., Genetic removal of p70 S6 kinase 1 corrects molecular, synaptic, and behavioral phenotypes in fragile X syndrome mice. Neuron 76 (2012), 325–337.
22. [22] Ronesi, J.A., Collins, K.A., Hays, S.A., Tsai, N.P., Guo, W., Birnbaum, S.G., et al. Disrupted Homer scaffolds mediate abnormal mGluR5 function in a mouse model of fragile X syndrome. Nat. Neurosci. 15 (2012), 431–440 (S1).
23. [23] Olmos-Serrano, J.L., Corbin, J.G., Burns, M.P., The GABA(A) receptor agonist THIP ameliorates specific behavioral deficits in the mouse model of fragile X syndrome. Dev. Neurosci. 33 (2011), 395–403.
24. [24] Udagawa, T., Farny, N.G., Jakovcevski, M., Kaphzan, H., Alarcon, J.M., Anilkumar, S., et al. Genetic and acute CPEB1 depletion ameliorate fragile X pathophysiology. Nat. Med. 19 (2013), 1473–1477.
25. [25] Samaco, R.C., McGraw, C.M., Ward, C.S., Sun, Y., Neul, J.L., Zoghbi, H.Y., Female Mecp2(+/−) mice display robust behavioral deficits on two different genetic backgrounds providing a framework for pre-clinical studies. Hum. Mol. Genet. 22 (2013), 96–109.
26. [26] Chao, H.T., Chen, H., Samaco, R.C., Xue, M., Chahrour, M., Yoo, J., et al. Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes. Nature 468 (2010), 263–269.
27. [27] Guy, J., Gan, J., Selfridge, J., Cobb, S., Bird, A., Reversal of neurological defects in a mouse model of Rett syndrome. Science 315 (2007), 1143–1147.
28. [28] Sztainberg, Y., Chen, H.M., Swann, J.W., Hao, S., Tang, B., Wu, Z., et al. Reversal of phenotypes in MECP2 duplication mice using genetic rescue or antisense oligonucleotides. Nature 528 (2015), 123–126.
29. [29] Ehninger, D., From genes to cognition in tuberous sclerosis: implications for mTOR inhibitor-based treatment approaches. Neuropharmacology 68 (2013), 97–105.
30. [30] Reith, R.M., McKenna, J., Wu, H., Hashmi, S.S., Cho, S.H., Dash, P.K., et al. Loss of Tsc2 in Purkinje cells is associated with autistic-like behavior in a mouse model of tuberous sclerosis complex. Neurobiol. Dis. 51 (2013), 93–103.
31. [31] Sato, A., Kasai, S., Kobayashi, T., Takamatsu, Y., Hino, O., Ikeda, K., et al. Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex. Nat. Commun., 3, 2012, 1292.
32. [32] Bader, P.L., Faizi, M., Kim, L.H., Owen, S.F., Tadross, M.R., Alfa, R.W., et al. Mouse model of Timothy syndrome recapitulates triad of autistic traits. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 15432–15437.
33. [33] Speed, H.E., Kouser, M., Xuan, Z., Reimers, J.M., Ochoa, C.F., Gupta, N., et al. Autism-Associated insertion mutation (InsG) of shank3 exon 21Causes impaired synaptic transmission and behavioral deficits. J. Neurosci. 35 (2015), 9648–9665.
34. [34] Giza, J., Urbanski, M.J., Prestori, F., Bandyopadhyay, B., Yam, A., Friedrich, V., et al. Behavioral and cerebellar transmission deficits in mice lacking the autism-linked gene islet brain-2. J. Neurosci. 30 (2010), 14805–14816.
35. [35] Kwon, C.H., Luikart, B.W., Powell, C.M., Zhou, J., Matheny, S.A., Zhang, W., et al. Pten regulates neuronal arborization and social interaction in mice. Neuron 50 (2006), 377–388.
36. [36] Scott-Van Zeeland, A.A., Abrahams, B.S., Alvarez-Retuerto, A.I., Sonnenblick, L.I., Rudie, J.D., Ghahremani, D., et al. Altered functional connectivity in frontal lobe circuits is associated with variation in the autism risk gene CNTNAP2. Sci. Transl. Med., 2, 2010, 56ra80.
37. [37] Moy, S.S., Riddick, N.V., Nikolova, V.D., Teng, B.L., Agster, K.L., Nonneman, R.J., et al. Repetitive behavior profile and supersensitivity to amphetamine in the C58/J mouse model of autism. Behav. Brain Res. 259 (2014), 200–214.
38. [38] LaSalle, J.M., Reiter, L.T., Chamberlain, S.J., Epigenetic regulation of UBE3A and roles in human neurodevelopmental disorders. Epigenomics 7 (2015), 1213–1228.
39. [39] Cook, E.H. Jr., Scherer, S.W., Copy-number variations associated with neuropsychiatric conditions. Nature 455 (2008), 919–923.
40. [40] Smith, S.E., Zhou, Y.D., Zhang, G., Jin, Z., Stoppel, D.C., Anderson, M.P., Increased gene dosage of Ube3a results in autism traits and decreased glutamate synaptic transmission in mice. Sci. Transl. Med., 3, 2011, 103ra97.
41. [41] Piochon, C., Kloth, A.D., Grasselli, G., Titley, H.K., Nakayama, H., Hashimoto, K., et al. Corrigendum: cerebellar plasticity and motor learning deficits in a copy-number variation mouse model of autism. Nat. Commun., 6, 2015, 6014.
42. [42] Zang, J.B., Nosyreva, E.D., Spencer, C.M., Volk, L.J., Musunuru, K., Zhong, R., et al. A mouse model of the human Fragile X syndrome I304N mutation. PLoS Genet., 5, 2009, e1000758.
43. [43] Pietropaolo, S., Guilleminot, A., Martin, B., D'Amato, F.R., Crusio, W.E., Genetic-background modulation of core and variable autistic-like symptoms in Fmr1 knock-out mice. PLoS One, 6, 2011, e17073.
44. [44] Han, K., Chen, H., Gennarino, V.A., Richman, R., Lu, H.C., Zoghbi, H.Y., Fragile X-like behaviors and abnormal cortical dendritic spines in cytoplasmic FMR1-interacting protein 2-mutant mice. Hum. Mol. Genet. 24 (2015), 1813–1823.
45. [45] Normand, E.A., Crandall, S.R., Thorn, C.A., Murphy, E.M., Voelcker, B., Browning, C., et al. Temporal and mosaic Tsc1 deletion in the developing thalamus disrupts thalamocortical circuitry, neural function, and behavior. Neuron 78 (2013), 895–909.
46. [46] Penagarikano, O., Abrahams, B.S., Herman, E.I., Winden, K.D., Gdalyahu, A., Dong, H., et al. Absence of CNTNAP2 leads to epilepsy, neuronal migration abnormalities, and core autism-related deficits. Cell 147 (2011), 235–246.
47. [47] Nakatani, J., Tamada, K., Hatanaka, F., Ise, S., Ohta, H., Inoue, K., et al. Abnormal behavior in a chromosome-engineered mouse model for human 15q11-13 duplication seen in autism. Cell 137 (2009), 1235–1246.
48. [48] Piochon, C., Kloth, A.D., Grasselli, G., Titley, H.K., Nakayama, H., Hashimoto, K., et al. Cerebellar plasticity and motor learning deficits in a copy-number variation mouse model of autism. Nat. Commun., 5, 2014, 5586.
49. [49] Shigemori, T., Sakai, A., Takumi, T., Itoh, Y., Suzuki, H., Altered microglia in the amygdala are involved in anxiety-related behaviors of a copy number variation mouse model of autism. J. Nippon Med. Sch. 82 (2015), 92–99.
50. [50] Zheng, F., Kasper, L.H., Bedford, D.C., Lerach, S., Teubner, B.J., Brindle, P.K., Mutation of the CH1 domain in the histone acetyltransferase CREBBP results in autism—relevant behaviors in mice. PLoS One, 11, 2016, e0146366.
51. [51] Meechan, D.W., Rutz, H.L., Fralish, M.S., Maynard, T.M., Rothblat, L.A., LaMantia, A.S., Cognitive ability is associated with altered medial frontal cortical circuits in the LgDel mouse model of 22q11. 2DS. Cereb Cortex 25 (2015), 1143–1151.
52. [52] Volk, L., Chiu, S.L., Sharma, K., Huganir, R.L., Glutamate synapses in human cognitive disorders. Annu. Rev. Neurosci. 38 (2015), 127–149.
53. [53] Zhang, X., Ruiz, B., Correa, P., Miller, M.J., Cellular dissociation of NF-kappaB and inducible nitric oxide synthase in Helicobacter pylori infection. Free Radical Biol. Med. 29 (2000), 730–735.
54. [54] Silverman, J.L., Turner, S.M., Barkan, C.L., Tolu, S.S., Saxena, R., Hung, A.Y., et al. Sociability and motor functions in Shank1 mutant mice. Brain Res. 1380 (2011), 120–137.
55. [55] Woo, G.H., Bak, E.J., Nakayama, H., Doi, K., Hydroxyurea (HU)-induced apoptosis in the mouse fetal lung. Exp. Mol. Pathol. 79 (2005), 59–67.
56. [56] El-Kordi, A., Winkler, D., Hammerschmidt, K., Kastner, A., Krueger, D., Ronnenberg, A., et al. Development of an autism severity score for mice using Nlgn4 null mutants as a construct-valid model of heritable monogenic autism. Behav. Brain Res. 251 (2013), 41–49.
57. [57] Ju, A., Hammerschmidt, K., Tantra, M., Krueger, D., Brose, N., Ehrenreich, H., Juvenile manifestation of ultrasound communication deficits in the neuroligin-4 null mutant mouse model of autism. Behav. Brain Res. 270 (2014), 159–164.
58. [58] Muller, C.L., Anacker, A.M., Veenstra-VanderWeele, J., The serotonin system in autism spectrum disorder: from biomarker to animal models. Neuroscience 321 (2016), 24–41.
59. [59] Mosienko, V., Beis, D., Alenina, N., Wohr, M., Reduced isolation-induced pup ultrasonic communication in mouse pups lacking brain serotonin. Mol. Autism, 6, 2015, 13.
60. [60] Veenstra-VanderWeele, J., Muller, C.L., Iwamoto, H., Sauer, J.E., Owens, W.A., Shah, C.R., et al. Autism gene variant causes hyperserotonemia, serotonin receptor hypersensitivity, social impairment and repetitive behavior. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 5469–5474.
61. [61] Restivo, L., Ferrari, F., Passino, E., Sgobio, C., Bock, J., Oostra, B.A., et al. Enriched environment promotes behavioral and morphological recovery in a mouse model for the fragile X syndrome. Proc. Natl. Acad. Sci. U. S. A. 102 (2005), 11557–11562.
62. [62] Becker, J.A., Clesse, D., Spiegelhalter, C., Schwab, Y., Le Merrer, J., Kieffer, B.L., Autistic-like syndrome in mu opioid receptor null mice is relieved by facilitated mGluR4 activity. Neuropsychopharmacology 39 (2014), 2049–2060.
63. [63] Aller, M.I., Pecoraro, V., Paternain, A.V., Canals, S., Lerma, J., Increased dosage of high-Affinity kainate receptor gene grik4 alters synaptic transmission and reproduces autism spectrum disorders features. J. Neurosci. 35 (2015), 13619–13628.
64. [64] Umeda, T., Takashima, N., Nakagawa, R., Maekawa, M., Ikegami, S., Yoshikawa, T., et al. Evaluation of Pax6 mutant rat as a model for autism. PLoS One, 5, 2010, e15500.
65. [65] Silverman, J.L., Smith, D.G., Rizzo, S.J., Karras, M.N., Turner, S.M., Tolu, S.S., et al. Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism. Sci. Transl. Med., 4, 2012, 131ra51.
66. [66] Won, H., Lee, H.R., Gee, H.Y., Mah, W., Kim, J.I., Lee, J., et al. Autistic-like social behaviour in Shank2-mutant mice improved by restoring NMDA receptor function. Nature 486 (2012), 261–265.
67. [67] Li, J., Chai, A., Wang, L., Ma, Y., Wu, Z., Yu, H., et al. Synaptic P-Rex1 signaling regulates hippocampal long-term depression and autism-like social behavior. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), E6964–72.
68. [68] Tian, D., Stoppel, L.J., Heynen, A.J., Lindemann, L., Jaeschke, G., Mills, A.A., et al. Contribution of mGluR5 to pathophysiology in a mouse model of human chromosome 16p11.2 microdeletion. Nat. Neurosci. 18 (2015), 182–184.
69. [69] Jamain, S., Radyushkin, K., Hammerschmidt, K., Granon, S., Boretius, S., Varoqueaux, F., et al. Reduced social interaction and ultrasonic communication in a mouse model of monogenic heritable autism. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 1710–1715.
70. [70] Radyushkin, K., Hammerschmidt, K., Boretius, S., Varoqueaux, F., El-Kordi, A., Ronnenberg, A., et al. Neuroligin-3-deficient mice: model of a monogenic heritable form of autism with an olfactory deficit. Genes Brain Behav. 8 (2009), 416–425.
71. [71] Zaccaria, K.J., Lagace, D.C., Eisch, A.J., McCasland, J.S., Resistance to change and vulnerability to stress: autistic-like features of GAP43-deficient mice. Genes Brain Behav. 9 (2010), 985–996.
72. [72] Zhao, Y., Fung, C., Shin, D., Shin, B.C., Thamotharan, S., Sankar, R., et al. Neuronal glucose transporter isoform 3 deficient mice demonstrate features of autism spectrum disorders. Mol. Psychiatry 15 (2010), 286–299.
73. [73] Hiramoto, T., Kang, G., Suzuki, G., Satoh, Y., Kucherlapati, R., Watanabe, Y., et al. Tbx1: identification of a 22q11: 2 gene as a risk factor for autism spectrum disorder in a mouse model. Hum. Mol. Genet. 20 (2011), 4775–4785.
74. [74] Horev, G., Ellegood, J., Lerch, J.P., Son, Y.E., Muthuswamy, L., Vogel, H., et al. Dosage-dependent phenotypes in models of 16p11: 2 lesions found in autism. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 17076–17081.
75. [75] Kyzar, E.J., Pham, M., Roth, A., Cachat, J., Green, J., Gaikwad, S., et al. Alterations in grooming activity and syntax in heterozygous SERT and BDNF knockout mice: the utility of behavior-recognition tools to characterize mutant mouse phenotypes. Brain Res. Bull. 89 (2012), 168–176.
76. [76] Grayton, H.M., Missler, M., Collier, D.A., Fernandes, C., Altered social behaviours in neurexin 1alpha knockout mice resemble core symptoms in neurodevelopmental disorders. PLoS One, 8, 2013, e67114.
77. [77] Greco, B., Manago, F., Tucci, V., Kao, H.T., Valtorta, F., Benfenati, F., Autism-related behavioral abnormalities in synapsin knockout mice. Behav. Brain Res. 251 (2013), 65–74.
78. [78] Jaramillo, T.C., Liu, S., Pettersen, A., Birnbaum, S.G., Powell, C.M., Autism-related neuroligin-3 mutation alters social behavior and spatial learning. Autism Res. 7 (2014), 264–272.
79. [79] Mohn, J.L., Alexander, J., Pirone, A., Palka, C.D., Lee, S.Y., Mebane, L., et al. Adenomatous polyposis coli protein deletion leads to cognitive and autism-like disabilities. Mol. Psychiatry 19 (2014), 1133–1142.
80. [80] Shimamoto, C., Ohnishi, T., Maekawa, M., Watanabe, A., Ohba, H., Arai, R., et al. Functional characterization of FABP3, 5 and 7 gene variants identified in schizophrenia and autism spectrum disorder and mouse behavioral studies. Hum. Mol. Genet. 23 (2014), 6495–6511.
81. [81] Sungur, A.O., Vorckel, K.J., Schwarting, R.K., Wohr, M., Repetitive behaviors in the Shank1 knockout mouse model for autism spectrum disorder: developmental aspects and effects of social context. J. Neurosci. Methods 234 (2014), 92–100.
82. [82] Sungur, A.O., Schwarting, R.K., Wohr, M., Early communication deficits in the Shank1 knockout mouse model for autism spectrum disorder: developmental aspects and effects of social context. Autism Res., 14, 2015.
83. [83] Wohr, M., Orduz, D., Gregory, P., Moreno, H., Khan, U., Vorckel, K.J., et al. Lack of parvalbumin in mice leads to behavioral deficits relevant to all human autism core symptoms and related neural morphofunctional abnormalities. Transl. Psychiatry, 5, 2015, e525.
84. [84] McFarlane, H.G., Kusek, G.K., Yang, M., Phoenix, J.L., Bolivar, V.J., Crawley, J.N., Autism-like behavioral phenotypes in BTBR T+ tf/J mice. Genes Brain Behav. 7 (2008), 152–163.
85. [85] Yang, M., Zhodzishsky, V., Crawley, J.N., Social deficits in BTBR T + tf/J mice are unchanged by cross-fostering with C57BL/6J mothers. Int. J. Dev. Neurosci. 25 (2007), 515–521.
86. [86] Ryan, B.C., Young, N.B., Crawley, J.N., Bodfish, J.W., Moy, S.S., Social deficits, stereotypy and early emergence of repetitive behavior in the C58/J inbred mouse strain. Behav. Brain Res. 208 (2010), 178–188.
87. [87] Hamilton, S.M., Spencer, C.M., Harrison, W.R., Yuva-Paylor, L.A., Graham, D.F., Daza, R.A., et al. Multiple autism-like behaviors in a novel transgenic mouse model. Behav. Brain Res. 218 (2011), 29–41.
88. [88] Jacome, L.F., Burket, J.A., Herndon, A.L., Deutsch, S.I., Genetically inbred Balb/c mice differ from outbred Swiss Webster mice on discrete measures of sociability: relevance to a genetic mouse model of autism spectrum disorders. Autism Res. 4 (2011), 393–400.
89. [89] Pearson, B.L., Pobbe, R.L., Defensor, E.B., Oasay, L., Bolivar, V.J., Blanchard, D.C., et al. Motor and cognitive stereotypies in the BTBR T + tf/J mouse model of autism. Genes Brain Behav. 10 (2011), 228–235.
90. [90] Zhang-James, Y., Yang, L., Middleton, F.A., Yang, L., Patak, J., Faraone, S.V., Autism-related behavioral phenotypes in an inbred rat substrain. Behav. Brain Res. 269 (2014), 103–114.
91. [91] Meador, K., Reynolds, M.W., Crean, S., Fahrbach, K., Probst, C., Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res. 81 (2008), 1–13.
92. [92] Ornoy, A., Valproic acid in pregnancy: how much are we endangering the embryo and fetus. Reprod. Toxicol. 28 (2009), 1–10.
93. [93] Williams, G., King, J., Cunningham, M., Stephan, M., Kerr, B., Hersh, J.H., Fetal valproate syndrome and autism: additional evidence of an association. Dev. Med. Child Neurol. 43 (2001), 202–206.
94. [94] Rasalam, A.D., Hailey, H., Williams, J.H., Moore, S.J., Turnpenny, P.D., Lloyd, D.J., et al. Characteristics of fetal anticonvulsant syndrome associated autistic disorder. Dev. Med. Child Neurol. 47 (2005), 551–555.
95. [95] Bromley, R.L., Mawer, G., Clayton-Smith, J., Baker, G.A., Liverpool, Manchester Neurodevelopment G. Autism spectrum disorders following in utero exposure to antiepileptic drugs. Neurology 71 (2008), 1923–1924.
96. [96] Christensen, J., Gronborg, T.K., Sorensen, M.J., Schendel, D., Parner, E.T., Pedersen, L.H., et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA 309 (2013), 1696–1703.
97. [97] Bambini-Junior, V., Rodrigues, L., Behr, G.A., Moreira, J.C., Riesgo, R., Gottfried, C., Animal model of autism induced by prenatal exposure to valproate: behavioral changes and liver parameters. Brain Res. 1408 (2011), 8–16.
98. [98] Kolozsi, E., Mackenzie, R.N., Roullet, F.I., deCatanzaro, D., Foster, J.A., Prenatal exposure to valproic acid leads to reduced expression of synaptic adhesion molecule neuroligin 3 in mice. Neuroscience 163 (2009), 1201–1210.
99. [99] Schneider, T., Przewlocki, R., Behavioral alterations in rats prenatally exposed to valproic acid: animal model of autism. Neuropsychopharmacology 30 (2005), 80–89.
100. [100] Massa, V., Cabrera, R.M., Menegola, E., Giavini, E., Finnell, R.H., Valproic acid-induced skeletal malformations: associated gene expression cascades. Pharmacogenet. Genomics 15 (2005), 787–800.
101. [101] Rodier, P.M., Ingram, J.L., Tisdale, B., Nelson, S., Romano, J., Embryological origin for autism: developmental anomalies of the cranial nerve motor nuclei. J. Comp. Neurol. 370 (1996), 247–261.
102. [102] Wagner, G.C., Reuhl, K.R., Cheh, M., McRae, P., Halladay, A.K., A new neurobehavioral model of autism in mice: pre- and postnatal exposure to sodium valproate. J. Autism Dev. Disord. 36 (2006), 779–793.
103. [103] Ingram, J.L., Peckham, S.M., Tisdale, B., Rodier, P.M., Prenatal exposure of rats to valproic acid reproduces the cerebellar anomalies associated with autism. Neurotoxicol. Teratol. 22 (2000), 319–324.
104. [104] Tsujino, N., Nakatani, Y., Seki, Y., Nakasato, A., Nakamura, M., Sugawara, M., et al. Abnormality of circadian rhythm accompanied by an increase in frontal cortex serotonin in animal model of autism. Neurosci. Res. 57 (2007), 289–295.
105. [105] Narita, M., Oyabu, A., Imura, Y., Kamada, N., Yokoyama, T., Tano, K., et al. Nonexploratory movement and behavioral alterations in a thalidomide or valproic acid-induced autism model rat. Neurosci. Res. 66 (2010), 2–6.
106. [106] Dufour-Rainfray, D., Vourc'h, P., Le Guisquet, A.M., Garreau, L., Ternant, D., Bodard, S., et al. Behavior and serotonergic disorders in rats exposed prenatally to valproate: a model for autism. Neurosci. Lett. 470 (2010), 55–59.
107. [107] Stanton, M.E., Peloso, E., Brown, K.L., Rodier, P., Discrimination learning and reversal of the conditioned eyeblink reflex in a rodent model of autism. Behav. Brain Res. 176 (2007), 133–140.
108. [108] Kim, K.C., Kim, P., Go, H.S., Choi, C.S., Yang, S.I., Cheong, J.H., et al. The critical period of valproate exposure to induce autistic symptoms in Sprague-Dawley rats. Toxicol. Lett. 201 (2011), 137–142.
109. [109] Markram, K., Rinaldi, T., La Mendola, D., Sandi, C., Markram, H., Abnormal fear conditioning and amygdala processing in an animal model of autism. Neuropsychopharmacology 33 (2008), 901–912.
110. [110] Bringas, M.E., Carvajal-Flores, F.N., Lopez-Ramirez, T.A., Atzori, M., Flores, G., Rearrangement of the dendritic morphology in limbic regions and altered exploratory behavior in a rat model of autism spectrum disorder. Neuroscience 241 (2013), 170–187.
111. [111] Favre, M.R., Barkat, T.R., Lamendola, D., Khazen, G., Markram, H., Markram, K., General developmental health in the VPA-rat model of autism. Front. Behav. Neurosci., 7, 2013, 88.
112. [112] Gao, J., Wang, X., Sun, H., Cao, Y., Liang, S., Wang, H., et al. Neuroprotective effects of docosahexaenoic acid on hippocampal cell death and learning and memory impairments in a valproic acid-induced rat autism model. Int. J. Dev. Neurosci. 49 (2016), 67–78.
113. [113] Kataoka, S., Takuma, K., Hara, Y., Maeda, Y., Ago, Y., Matsuda, T., Autism-like behaviours with transient histone hyperacetylation in mice treated prenatally with valproic acid. Int. J. Neuropsychopharmacol. 16 (2013), 91–103.
114. [114] Lucchina, L., Depino, A.M., Altered peripheral and central inflammatory responses in a mouse model of autism. Autism Res. 7 (2014), 273–289.
115. [115] Hara, Y., Ago, Y., Taruta, A., Katashiba, K., Hasebe, S., Takano, E., et al. Improvement by methylphenidate and atomoxetine of social interaction deficits and recognition memory impairment in a mouse model of valproic acid-induced autism. Autism Res., 14, 2015.
116. [116] Hara, Y., Takuma, K., Takano, E., Katashiba, K., Taruta, A., Higashino, K., et al. Reduced prefrontal dopaminergic activity in valproic acid-treated mouse autism model. Behav. Brain Res. 289 (2015), 39–47.
117. [117] Gandal, M.J., Edgar, J.C., Ehrlichman, R.S., Mehta, M., Roberts, T.P., Siegel, S.J., Validating gamma oscillations and delayed auditory responses as translational biomarkers of autism. Biol. Psychiatry 68 (2010), 1100–1106.
118. [118] Mehta, M.V., Gandal, M.J., Siegel, S.J., mGluR5-antagonist mediated reversal of elevated stereotyped, repetitive behaviors in the VPA model of autism. PLoS One, 6, 2011, e26077.
119. [119] Cheaha, D., Bumrungsri, S., Chatpun, S., Kumarnsit, E., Characterization of in utero valproic acid mouse model of autism by local field potential in the hippocampus and the olfactory bulb. Neurosci. Res. 98 (2015), 28–34.
120. [120] Turnbull, D.M., Rawlins, M.D., Weightman, D., Chadwick, D.W., Plasma concentrations of sodium valproate: their clinical value. Ann. Neurol. 14 (1983), 38–42.
121. [121] Binkerd, P.E., Rowland, J.M., Nau, H., Hendrickx, A.G., Evaluation of valproic acid (VPA) developmental toxicity and pharmacokinetics in Sprague-Dawley rats. Fundam. Appl. Toxicol. 11 (1988), 485–493.
122. [122] Haddad, P.M., Das, A., Ashfaq, M., Wieck, A., A review of valproate in psychiatric practice. Expert Opin. Drug Metab. Toxicol. 5 (2009), 539–551.
123. [123] Loscher, W., Nau, H., Valproic acid: metabolite concentrations in plasma and brain, anticonvulsant activity, and effects on GABA metabolism during subacute treatment in mice. Arch. Int. Pharmacodyn. Ther. 257 (1982), 20–31.
124. [124] Roullet, F.I., Wollaston, L., Decatanzaro, D., Foster, J.A., Behavioral and molecular changes in the mouse in response to prenatal exposure to the anti-epileptic drug valproic acid. Neuroscience 170 (2010), 514–522.
125. [125] Olde Loohuis, N.F., Kole, K., Glennon, J.C., Karel, P., Van der Borg, G., Van Gemert, Y., et al. Elevated microRNA-181c and microRNA-30d levels in the enlarged amygdala of the valproic acid rat model of autism. Neurobiol. Dis. 80 (2015), 42–53.
126. [126] Schneider, T., Roman, A., Basta-Kaim, A., Kubera, M., Budziszewska, B., Schneider, K., et al. Gender-specific behavioral and immunological alterations in an animal model of autism induced by prenatal exposure to valproic acid. Psychoneuroendocrinology 33 (2008), 728–740.
127. [127] Yochum, C.L., Dowling, P., Reuhl, K.R., Wagner, G.C., Ming, X., VPA-induced apoptosis and behavioral deficits in neonatal mice. Brain Res. 1203 (2008), 126–132.
128. [128] Wang, C.Y., Cheng, C.W., Wang, W.H., Chen, P.S., Tzeng, S.F., Postnatal stress induced by injection with valproate leads to developing emotional disorders along with molecular and cellular changes in the hippocampus and amygdala. Mol. Neurobiol., 12, 2015.
129. [129] Oguchi-Katayama, A., Monma, A., Sekino, Y., Moriguchi, T., Sato, K., Comparative gene expression analysis of the amygdala in autistic rat models produced by pre- and post-natal exposures to valproic acid. J. Toxicol. Sci. 38 (2013), 391–402.
130. [130] Kim, J.W., Seung, H., Kwon, K.J., Ko, M.J., Lee, E.J., Oh, H.A., et al. Subchronic treatment of donepezil rescues impaired social, hyperactive, and stereotypic behavior in valproic acid-induced animal model of autism. PLoS One, 9, 2014, e104927.
131. [131] Kang, J., Kim, E., Suppression of NMDA receptor function in mice prenatally exposed to valproic acid improves social deficits and repetitive behaviors. Front. Mol. Neurosci., 8, 2015, 17.
132. [132] Al-Amin, M.M., Rahman, M.M., Khan, F.R., Zaman, F., Mahmud Reza, H., Astaxanthin improves behavioral disorder and oxidative stress in prenatal valproic acid-induced mice model of autism. Behav. Brain Res. 286 (2015), 112–121.
133. [133] Frisch, C., Husch, K., Angenstein, F., Kudin, A., Kunz, W., Elger, C.E., et al. Dose-dependent memory effects and cerebral volume changes after in utero exposure to valproate in the rat. Epilepsia 50 (2009), 1432–1441.
134. [134] de Theije, C.G., Koelink, P.J., Korte-Bouws, G.A., Lopes da Silva, S., Korte, S.M., Olivier, B., et al. Intestinal inflammation in a murine model of autism spectrum disorders. Brain Behav. Immun. 37 (2014), 240–247.
135. [135] Pragnya, B., Kameshwari, J.S., Veeresh, B., Ameliorating effect of piperine on behavioral abnormalities and oxidative markers in sodium valproate induced autism in BALB/C mice. Behav. Brain Res. 270 (2014), 86–94.
136. [136] Chomiak, T., Karnik, V., Block, E., Hu, B., Altering the trajectory of early postnatal cortical development can lead to structural and behavioural features of autism. BMC Neurosci., 11, 2010, 102.
137. [137] Reynolds, S., Millette, A., Devine, D.P., Sensory and motor characterization in the postnatal valproate rat model of autism. Dev. Neurosci. 34 (2012), 258–267.
138. [138] Giarelli, E., Wiggins, L.D., Rice, C.E., Levy, S.E., Kirby, R.S., Pinto-Martin, J., et al. Sex differences in the evaluation and diagnosis of autism spectrum disorders among children. Disability Health J. 3 (2010), 107–116.
139. [139] Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., et al. Identification of a primary target of thalidomide teratogenicity. Science 327 (2010), 1345–1350.
140. [140] Stromland, K., Nordin, V., Miller, M., Akerstrom, B., Gillberg, C., Autism in thalidomide embryopathy: a population study. Dev. Med. Child Neurol. 36 (1994), 351–356.
141. [141] Narita, N., Kato, M., Tazoe, M., Miyazaki, K., Narita, M., Okado, N., Increased monoamine concentration in the brain and blood of fetal thalidomide- and valproic acid-exposed rat: putative animal models for autism. Pediatr. Res. 52 (2002), 576–579.
142. [142] Gonzalez, C.H., Marques-Dias, M.J., Kim, C.A., Sugayama, S.M., Da Paz, J.A., Huson, S.M., et al. Congenital abnormalities in Brazilian children associated with misoprostol misuse in first trimester of pregnancy. Lancet 351 (1998), 1624–1627.
143. [143] Verzijl, H.T., van der Zwaag, B., Cruysberg, J.R., Padberg, G.W., Mobius syndrome redefined: a syndrome of rhombencephalic maldevelopment. Neurology 61 (2003), 327–333.
144. [144] Stromland, K., Sjogreen, L., Miller, M., Gillberg, C., Wentz, E., Johansson, M., et al. Mobius sequence–a Swedish multidiscipline study. Eur. J. Paediatr. Neurol. 6 (2002), 35–45.
145. [145] Koenig, C.M., Walker, C.K., Qi, L., Pessah, I.N., Berman, R.F., Lack of evidence for neonatal misoprostol neurodevelopmental toxicity in C57BL6/J mice. PLoS One, 7, 2012, e38911.
146. [146] MacFabe, D.F., Cain, D.P., Rodriguez-Capote, K., Franklin, A.E., Hoffman, J.E., Boon, F., et al. Neurobiological effects of intraventricular propionic acid in rats: possible role of short chain fatty acids on the pathogenesis and characteristics of autism spectrum disorders. Behav. Brain Res. 176 (2007), 149–169.
147. [147] MacFabe, D.F., Cain, N.E., Boon, F., Ossenkopp, K.P., Cain, D.P., Effects of the enteric bacterial metabolic product propionic acid on object-directed behavior, social behavior, cognition, and neuroinflammation in adolescent rats: relevance to autism spectrum disorder. Behav. Brain Res. 217 (2011), 47–54.
148. [148] Shultz, S.R., MacFabe, D.F., Ossenkopp, K.P., Scratch, S., Whelan, J., Taylor, R., et al. Intracerebroventricular injection of propionic acid, an enteric bacterial metabolic end-product, impairs social behavior in the rat: implications for an animal model of autism. Neuropharmacology 54 (2008), 901–911.
149. [149] Thomas, R.H., Meeking, M.M., Mepham, J.R., Tichenoff, L., Possmayer, F., Liu, S., et al. The enteric bacterial metabolite propionic acid alters brain and plasma phospholipid molecular species: further development of a rodent model of autism spectrum disorders. J. Neuroinflammation, 9, 2012, 153.
150. [150] Patterson, P.H., Immune involvement in schizophrenia and autism: etiology, pathology and animal models. Behav. Brain Res. 204 (2009), 313–321.
151. [151] Lancaster, K., Dietz, D.M., Moran, T.H., Pletnikov, M.V., Abnormal social behaviors in young and adult rats neonatally infected with Borna disease virus. Behav. Brain Res. 176 (2007), 141–148.
152. [152] Lieb, K., Staeheli, P., Borna disease virus–does it infect humans and cause psychiatric disorders. J. Clin. Virol. 21 (2001), 119–127.
153. [153] Boksa, P., Effects of prenatal infection on brain development and behavior: a review of findings from animal models. Brain Behav. Immun. 24 (2010), 881–897.
154. [154] Carpentier, P.A., Dingman, A.L., Palmer, T.D., Placental TNF-alpha signaling in illness-induced complications of pregnancy. Am. J. Pathol. 178 (2011), 2802–2810.
155. [155] Ohkawara, T., Katsuyama, T., Ida-Eto, M., Narita, N., Narita, M., Maternal viral infection during pregnancy impairs development of fetal serotonergic neurons. Brain Dev. 37 (2015), 88–93.
156. [156] Xuan, I.C., Hampson, D.R., Gender-dependent effects of maternal immune activation on the behavior of mouse offspring. PLoS One, 9, 2014, e104433.